Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report

被引:0
作者
Kinnosuke Matsumoto
Takayuki Shiroyama
Noriyasu Hashida
Kotaro Miyake
Yuji Yamamoto
Tomoki Kuge
Midori Yoneda
Makoto Yamamoto
Yujiro Naito
Yasuhiko Suga
Kiyoharu Fukushima
Shohei Koyama
Kota Iwahori
Haruhiko Hirata
Izumi Nagatomo
Yoshito Takeda
Atsushi Kumanogoh
机构
[1] Osaka University,Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine
[2] Osaka University,Department of Ophthalmology, Graduate School of Medicine
来源
Angiogenesis | 2022年 / 25卷
关键词
Lung adenocarcinoma; Choroidal metastasis; Ramucirumab; Docetaxel; Case report;
D O I
暂无
中图分类号
学科分类号
摘要
We report a unique case of advanced non-small cell lung cancer that exhibited the opposite response to its unilateral choroidal metastases upon ramucirumab plus docetaxel treatment. A combination of cisplatin, pemetrexed, and pembrolizumab was administered as first-line treatment, resulting in shrinkage of all the lesions. However, although the patient was continued on a course of pembrolizumab, all the lesions had recurred approximately two months later. Ramucirumab plus docetaxel, administered as sequential treatment, resulted in maintained shrinkage of the choroidal lesions, yet all the other lesions progressed. Ramucirumab may be a suitable therapy for choroidal metastases, especially if administered immediately after immunotherapy.
引用
收藏
页码:147 / 149
页数:2
相关论文
共 28 条
[1]  
Shields CL(1997)Survey of 520 eyes with uveal metastases Ophthalmology 104 1265-1276
[2]  
Shields JA(2019)New concepts in the diagnosis and management of choroidal metastases Prog Retin Eye Res 68 144-176
[3]  
Gross NE(2021)Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes Nat Rev Clin Oncol 18 527-540
[4]  
Schwartz GP(2007)Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up Eye 21 566-567
[5]  
Lally SE(2020)Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment Lung Cancer 144 71-75
[6]  
Mathis T(2020)Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV Clin Med Insights Oncol 14 1179554920951358-undefined
[7]  
Jardel P(2021)Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review Hum Vaccin Immunother undefined undefined-undefined
[8]  
Loria O(undefined)undefined undefined undefined undefined-undefined
[9]  
Huinen ZR(undefined)undefined undefined undefined undefined-undefined
[10]  
Huijbers EJM(undefined)undefined undefined undefined undefined-undefined